Identifying the Best Follow up Approach for People Who Have Had Treatment to Cure Newly Diagnosed Prostate Cancer

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age18+
SponsorImperial College London

About this trial

Over 20,000 patients a year in the UK get surgery or radiotherapy to cure their prostate cancer. These men then undergo regular check-ups to manage potential side effects and see if cancer recurs so it can be treated quickly. The organisation of these check-ups varies across the country as it is not known which approach is best. The four different established approaches are (i) check-ups performed in hospital outpatients by the same team that provided treatment; (ii) patients seen regularly by their GP with hospital referral as necessary; (iii) planned shared care between general practice and hospital follow up; or (iv) patients supported to provide checks on themselves (self-care) and reaching out to a doctor or a nurse when required. This study will compare these options to establish which is best for patients and makes the best use of the NHS resources.

Eligibility criteria

Qualifiers

Having newly-diagnosed non-metastatic, clinically localised prostate cancer (ICD-10 code C61) in the Cancer Registry between 1 January 2018 and 31 December 2023;

Age 18 or over at diagnosis;

Completed primary curative treatment at an eligible hospital between 1 January 2019 and 31 December 2023 with either: radical radiotherapy +/- hormones, or radical prostatectomy with curative intent +/- lymphadenectomy, or focal therapy, in keeping with local practice;

Alive with no disease progression or metastasis 6 months after the date of completion of primary curative treatment.

Disqualifiers

Men who are treated for metastatic cancer; or receiving palliative prostate cancer care;

Men who have opted out of their data being used as part of national routine data sets will be excluded (https://digital.nhs.uk/services/national-data-opt-out).

Alive;

Have achieved between three to four and a half years of follow up (from completion of initial curative treatment) during the survey period.

Trial design

Treatments tested in this trial

  • Hospital based follow up
  • Primary care based follow up
  • Planned shared care follow up
  • Self-management

Treatment groups

100,000 Participants
are divided into 4 treatment groups

Sponsors and collaborators

Imperial College London

Lead sponsor

London School of Hygiene and Tropical Medicine

Collaborator

University of Aberdeen

Collaborator

University of Leeds

Collaborator

Cardiff University

Collaborator

University of Sheffield

Collaborator

University of Southampton

Collaborator

University College, London

Collaborator

Royal Marsden NHS Foundation Trust

Collaborator

North Bristol NHS Trust

Collaborator

Cardiff and Vale University Health Board

Collaborator

Liverpool University Hospitals NHS Foundation Trust

Collaborator

National Institute for Health Research, United Kingdom

Collaborator